Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarker-based staging of Alzheimer disease: rationale and clinical applications.
Therriault J, Schindler SE, Salvadó G, Pascoal TA, Benedet AL, Ashton NJ, Karikari TK, Apostolova L, Murray ME, Verberk I, Vogel JW, La Joie R, Gauthier S, Teunissen C, Rabinovici GD, Zetterberg H, Bateman RJ, Scheltens P, Blennow K, Sperling R, Hansson O, Jack CR Jr, Rosa-Neto P. Therriault J, et al. Among authors: scheltens p. Nat Rev Neurol. 2024 Apr;20(4):232-244. doi: 10.1038/s41582-024-00942-2. Epub 2024 Mar 1. Nat Rev Neurol. 2024. PMID: 38429551 Review.
Biomarkers for Alzheimer's disease. Which way to go?
Teunissen CE, Scheltens P. Teunissen CE, et al. Among authors: scheltens p. Neurobiol Aging. 2004 Jul;25(6):695-6. doi: 10.1016/j.neurobiolaging.2003.08.013. Neurobiol Aging. 2004. PMID: 15165690 No abstract available.
Use of proteomic approaches to identify disease biomarkers.
Teunissen CE, Scheltens P. Teunissen CE, et al. Among authors: scheltens p. Lancet Neurol. 2007 Dec;6(12):1036-7. doi: 10.1016/S1474-4422(07)70276-4. Lancet Neurol. 2007. PMID: 18031700 No abstract available.
Revised research diagnostic criteria for Alzheimer's disease.
Gauthier S, Dubois B, Feldman H, Scheltens P. Gauthier S, et al. Among authors: scheltens p. Lancet Neurol. 2008 Aug;7(8):668-70. doi: 10.1016/S1474-4422(08)70146-7. Lancet Neurol. 2008. PMID: 18635012 No abstract available.
Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.
van Straaten EC, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ, Jack CR Jr, DeCarli C; Alzheimer's Disease Cooperative Study Group. van Straaten EC, et al. Among authors: scheltens p. J Neurol. 2008 Sep;255(9):1302-8. doi: 10.1007/s00415-008-0874-y. Epub 2008 Sep 25. J Neurol. 2008. PMID: 18825439 Free PMC article. Clinical Trial.
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K. Visser PJ, et al. Among authors: scheltens p. Lancet Neurol. 2009 Jul;8(7):619-27. doi: 10.1016/S1474-4422(09)70139-5. Epub 2009 Jun 10. Lancet Neurol. 2009. PMID: 19523877
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K. Mattsson N, et al. Among authors: scheltens p. JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064. JAMA. 2009. PMID: 19622817
1,253 results